I-MAB

IMAB

Company Profile

  • Business description

    I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People’s Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).

  • Contact

    2440 Research Boulevard
    Suite 400
    RockvilleMD20850
    USA

    T: +1 240 745-6330

    https://www.i-mabbiopharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2024

    Employees

    220

I-MAB News & Analysis

stocks

10 of the cheapest US stocks of 2022

One silver lining of the bear market is half the US stocks followed by Morningstar analysts are now undervalued.
stocks

Chinese biotech: Buy the dip?

Morningstar looks at two diversified Chinese biotech names.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,687.6054.500.63%
CAC 407,255.0141.690.58%
DAX 4019,322.59176.420.92%
Dow JONES (US)44,296.51426.160.97%
FTSE 1008,262.08112.811.38%
HKSE19,287.2257.250.30%
NASDAQ19,003.6531.230.16%
Nikkei 22538,941.87658.021.72%
NZX 50 Index13,128.1686.260.66%
S&P 5005,969.3420.630.35%
S&P/ASX 2008,443.6049.800.59%
SSE Composite Index3,274.917.720.24%

Market Movers